Pharmaceutical firm GSK opens $130m manufacturing facility in Singapore

The facility is expected to produce anemia and HIV drugs faster.

Multinational pharmaceutical company GlaxoSmithKlyne (GSK) launched two new manufacturing continuous facility and an expanded production building at its Jurong site.

According to GSK, the new and expanded sites will allow the faster production of drugs and Active Pharmaceutical Ingredients (APIs) for clinical trials.

The expansion also reportedly streamlines the manufacturing of APIs which are important for the production of Dolutegravir (Tivicay), a medication used for HIV/AIDS.

Daprodustat, a new oral drug for treating anaemia associated with chronic kidney disease, will reportedly be the first New Chemical Entity to be developed in the facility. GSK expects the new manufacturing process to reduce Daprodustat’s production time.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia